Literature DB >> 11316087

Protection of research subjects with emphasis on protocols involving radiation.

K L Classic1, B L Porter, E P DiMagno.   

Abstract

Approval by an institutional review board (IRB) or human studies committee must be obtained prior to conducting human subject research. Historically this was not the case, and human subjects were injured as a result. Because there has been and still remains an inevitable conflict of interest for researchers, instititions that perform human research must follow regulations designed to protect human subjects contained in the Code of Federal Regulations, if the research is federally funded. Two federal agencies provide oversight for IRB activities: the Food and Drug Administration (FDA) and a National Institutes of Health Office for Human Research Protection (OHRP), formerly the Office for Protection from Research Risks (OPRR). These agencies are charged with the implementation of rules related to ethical and legal obligations of researchers and their institutions. The institution's role, by means of an IRB, is to adhere to principles of the Belmont Report and to set forth ethical principles, policies, and procedures for protecting the rights and welfare of human subjects. The researchers' role is to conduct their research ethically while maximizing benefits and minimizing harm. Studies involving radiation exposure of human subjects add another level of risk that must be evaluated by an IRB with assistance of a radiation expert or radiation safety committee (RSC). This paper will look at regulatory aspects of human research, IRB responsibilities overall and as they relate to radiation exposure of subjects, and the role of the RSC.

Entities:  

Mesh:

Year:  2001        PMID: 11316087     DOI: 10.1097/00004032-200105001-00009

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  1 in total

1.  GCP compliance and readability of informed consent forms from an emerging hub for clinical trials.

Authors:  Satish Chandrasekhar Nair; Halah Ibrahim
Journal:  Perspect Clin Res       Date:  2015 Apr-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.